Donath-Landsteiner Hemolytic Anemia Workup

  • Author: Trisha Simone Tavares, MD; Chief Editor: Max J Coppes, MD, PhD, MBA   more...
 
Updated: Feb 6, 2012
 

Approach Considerations

The diagnosis of Donath-Landsteiner hemolytic anemia (DLHA) depends on the performance of the specific test to detect the causative autoantibody, the Donath-Landsteiner (D-L) autoantibody. The clinician must have a high index of suspicion. Donath-Landsteiner hemolytic anemia can be confused with cold agglutinin disease and with warm-antibody autoimmune hemolytic anemia.

Next

Complete Blood Cell Count and Peripheral Smear

Anemia may be mild, moderate, or severe. Anemia is usually normocytic and normochromic. However, the mean corpuscular volume (MCV) may be elevated when reticulocytosis is present. Reticulocytosis does not develop until later in the disease; in the early stages, reticulocytopenia is often present.

Leukopenia may be present early, but the leukocyte count then improves to within the reference range or higher. Leukocytosis may be present during hemolytic episodes.

The peripheral blood smear exhibits spherocytosis, polychromasia, nucleated RBCs, anisocytosis, poikilocytosis, and sometimes erythrophagocytosis by neutrophils (see the images below).[13, 14]

Blood smear showing spherocytosis, polychromatophiBlood smear showing spherocytosis, polychromatophilia, and erythrophagocytosis by neutrophils. Blood smear showing spherocytosis, polychromatophiBlood smear showing spherocytosis, polychromatophilia, and erythrophagocytosis by neutrophils.
Previous
Next

Blood Typing

Blood typing should be performed on all patients in the event a blood transfusion is needed. Unfortunately, the presence of autoantibodies may interfere with typing. The autoantibody may react with the RBCs of all potential donors, making detection of alloantibodies difficult. Compatibility testing can be improved by performing the test at 37°C.

Previous
Next

Direct Antiglobulin Test

The direct antiglobulin test (DAT) with anti-IgG usually produces negative results because of dissociation of IgG from the RBC surface at warm temperatures. The DAT may produce weakly positive results if run at a cold temperature. A positive DAT result is due to C3.

Previous
Next

Indirect Antiglobulin Test

The indirect antiglobulin test, if performed, must be carried out at a cold temperature.

Assays using labeled monoclonal anti-immunoglobulin (Ig) G are preferable. The autoantibody is IgG with anti-P specificity, although the specificity may be for other antigens. The titer is usually less than 1:100.

Donath-Landsteiner Bithermic Hemolytic Test

Positive results are demonstrated by incubation in cold, followed by incubation at 37°C in the presence of complement.

This is a hemolytic assay in which the patient's serum is incubated with normal RBCs and complement at 4°C to allow the early components of complement to be fixed. Subsequently, the specimen is incubated at 37°C in order to allow the later components of complement to be activated. The membrane attack complex lyses the RBCs.

The procedure for this test is as follows:

  • Incubate normal papainized group O RBCs (papainization exposes RBC membrane P -antigen sites) and normal serum (as complement source) with the patient's serum (containing D-L antibody) at 0-4°C; the use of papainized pooled O-cells results in exposure of more antigen sites on the cell membrane to the antibody.
  • Incubate a second group of samples, as above, at 37°C
  • Incubate a third group first at 0-4°C for 30 minutes, then at 37°C for 60 minutes

The presence of hemolysis in the third group without hemolysis in either the first or second group of samples constitutes a positive test result and a diagnosis of Donath-Landsteiner hemolytic anemia.

The Donath-Landsteiner test has a low sensitivity, and results are positive only when the serum antibody titer is high and the test is performed precisely.

A false negative test may be seen if the following is present:

  • Low level of antibody due to consumption during hemolysis
  • Low complement levels from consumption during hemolysis (this can be prevented by mixing the patient sample with fresh normal donor serum as a source of complement)
  • If donor serum as a source of complement is added, presence of globoside in the serum may neutralize the Donath-Landsteiner (D-L) antibody[15]

Autoantibody specificity may be indicated if D-L test result is positive. Almost all cases are associated with anti-P specificity.

Previous
Next

Blood Chemistry and Serology

Evidence of hemolysis is elevated levels of indirect bilirubin and lactate dehydrogenase in the presence of a decreased haptoglobin level.

Anemia may be mild, moderate, or severe.

Blood urea nitrogen (BUN) and creatinine levels may be elevated if renal insufficiency is present.

Complement levels are typically decreased.

On serologic testing, results for syphilis, mycoplasmal infection, or viruses (eg, influenza A, measles, mumps, adenovirus, cytomegalovirus, varicella, Epstein-Barr virus [EBV]) may be positive, depending on the underlying cause.

Previous
Next

Peripheral Blood Smear

Microscopic examination of the peripheral blood may show RBC agglutination and anisopoikilocytosis. Erythrophagocytosis by neutrophils may also be seen.[13]

Reticulocytosis is expected. If the etiology of the condition is parvovirus B-19 infection, reticulocytopenia may occur.

Previous
Next

Urinalysis

Hemoglobinuria, methemoglobinuria, and hemosiderinuria are often present but are not required for diagnosis.

Proteinuria may be present.

Previous
 
 
Contributor Information and Disclosures
Author

Trisha Simone Tavares, MD  Assistant Professor of Pediatrics, Attending Physician, Department of Pediatrics, Section of Hematology and Oncology, Center for Children's Cancer and Blood Disorders, Golisano Children's Hospital, State University of New York Upstate Medical University; Attending Physician, Department of Pediatrics, Crouse Hospital

Trisha Simone Tavares, MD is a member of the following medical societies: Children's Oncology Group and Medical Society of the State of New York

Disclosure: Nothing to disclose.

Coauthor(s)

M Monica Gramatges, MD  Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine

M Monica Gramatges, MD is a member of the following medical societies: American Association for Cancer Research, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Children's Oncology Group

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA  Senior Vice President, Center for Cancer and Blood Disorders, Children's National Medical Center; Professor of Medicine, Oncology, and Pediatrics, Georgetown University School of Medicine; Clinical Professor of Pediatrics, George Washington University School of Medicine and Health Sciences

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Nicolas A Camilo, MD Consulting Staff, Division of Pediatric Hematology-Oncology, Mountain States Tumor Institute, St Luke's Regional Medical Center

Nicolas A Camilo, MD is a member of the following medical societies: American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Gary D Crouch, MD Program Director of Pediatric Hematology-Oncology Fellowship, Department of Pediatrics, Associate Professor, Uniformed Services University of the Health Sciences

Gary D Crouch, MD is a member of the following medical societies: American Academy of Pediatrics and American Society of Hematology

Disclosure: Nothing to disclose.

Michael R Jeng, MD Associate Professor, Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine

Michael R Jeng, MD is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Histiocyte Society

Disclosure: Nothing to disclose.

Gary R Jones, MD Associate Medical Director, Clinical Development, Berlex Laboratories

Gary R Jones, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Pediatric Hematology/Oncology, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Thomas W Loew, MD Clinical Professor of Pediatrics, Division Director of Pediatric Hematology/Oncology, University of Missouri Children's Hospital

Thomas W Loew, MD is a member of the following medical societies: American Academy of Pediatrics, American Academy of Pediatrics, American College of Physician Executives, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Children's Oncology Group

Disclosure: Genzyme Grant/research funds Independent contractor; Genzyme Honoraria Speaking and teaching; Amicus Grant/research funds Independent contractor; Purdue Pharmaceuticals Grant/research funds Independent contractor

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Donath J LK. Uber paroxysmale Hamoglobinurie. Munchener Medizinische Wochenschrift. 1904;51:1590-3.

  2. Bird GW. Paroxysmal cold haemoglobinuria. Br J Haematol. Oct 1977;37(2):167-71. [Medline].

  3. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. Apr 2002;69(4):258-71. [Medline].

  4. Sivakumaran M, Murphy PT, Booker DJ, Wood JK, Stamps R, Sokol RJ. Paroxysmal cold haemoglobinuria caused by non-Hodgkin's lymphoma. Br J Haematol. Apr 1999;105(1):278-9. [Medline].

  5. Sharara AI, Hillsley RE, Wax TD, Rosse WF. Paroxysmal cold hemoglobinuria associated with non-Hodgkin's lymphoma. South Med J. Mar 1994;87(3):397-9. [Medline].

  6. Lippman SM, Winn L, Grumet FC, Levitt LJ. Evans' syndrome as a presenting manifestation of atypical paroxysmal cold hemoglobinuria. Am J Med. May 1987;82(5):1065-72. [Medline].

  7. Petz LD. Cold antibody autoimmune hemolytic anemias. Blood Rev. Jan 2008;22(1):1-15. [Medline].

  8. Sokol RJ, Booker DJ, Stamps R. Erythropoiesis: Paroxysmal Cold Haemoglobinuria: A Clinico-Pathological Study of Patients with a Positive Donath-Landsteiner Test. Hematology. 1999;4(2):137-164. [Medline].

  9. Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis associated with Donath-Landsteiner antibodies. Acta Haematol. 1982;68(4):268-77. [Medline].

  10. Gottsche B, Salama A, Mueller-Eckhardt C. Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases. Vox Sang. 1990;58(4):281-6. [Medline].

  11. Wolach B, Heddle N, Barr RD, Zipursky A, Pai KR, Blajchman MA. Transient Donath-Landsteiner haemolytic anaemia. Br J Haematol. Jul 1981;48(3):425-34. [Medline].

  12. Taylor CJ, Neilson JR, Chandra D, Ibrahim Z. Recurrent paroxysmal cold haemoglobinuria in a 3-year-old child: a case report. Transfus Med. Oct 2003;13(5):319-21. [Medline].

  13. Heddle NM. Acute paroxysmal cold hemoglobinuria. Transfus Med Rev. Jul 1989;3(3):219-29. [Medline].

  14. Hernandez JA, Steane SM. Erythrophagocytosis by segmented neutrophils in paroxysmal cold hemoglobinuria. Am J Clin Pathol. Jun 1984;81(6):787-9. [Medline].

  15. Win N, Stamps R, Knight R. Paroxysmal cold haemoglobinuria/Donath-Landsteiner test. Transfus Med. Jun 2005;15(3):254. [Medline].

  16. [Guideline] Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for neonates and older children. Br J Haematol. Feb 2004;124(4):433-53. [Medline]. [Full Text].

  17. Koppel A, Lim S, Osby M, Garratty G, Goldfinger D. Rituximab as successful therapy in a patient with refractory paroxysmal cold hemoglobinuria. Transfusion. Oct 2007;47(10):1902-4. [Medline].

  18. Roy-Burman A, Glader BE. Resolution of severe Donath-Landsteiner autoimmune hemolytic anemia temporally associated with institution of plasmapheresis. Crit Care Med. Apr 2002;30(4):931-4. [Medline].

Previous
Next
 
Blood smear showing spherocytosis, polychromatophilia, and erythrophagocytosis by neutrophils.
Blood smear showing spherocytosis, polychromatophilia, and erythrophagocytosis by neutrophils.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.